Advertisement

Topics

Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer

13:46 EST 14 Nov 2017 | SCRIP

The German pharma signs collaboration to develop and commercialize larotrectinib and a follow-on, under a structure that enables Loxo to...

      

Related Stories

 

Original Article: Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer

NEXT ARTICLE

More From BioPortfolio on "Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...